LMR Partners’s Novo Nordisk NVO Stock Holding History

LMR Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-285,000	Closed	-$10.5M	–	1699
2026 Q1	$10.5M	Sell	285,000 -357,300	-56%	-$16.9M	0.02%	404
2025 Q4	$32.7M	Buy	642,300 +232,300	+57%	+$11.9M	0.06%	141
2025 Q3	$22.8M	Buy	410,000 +284,900	+228%	+$16.7M	0.1%	155
2025 Q2	$8.63M	Buy	125,100 +115,100	+1,151%	+$7.83M	0.06%	315
2025 Q1	$694K	Sell	10,000 -10,000	-50%	-$826K	0.01%	856
2024 Q4	$1.72M	Sell	20,000 -15,900	-44%	-$1.72M	0.01%	637
2024 Q3	$4.27M	Buy	+35,900	New	+$4.79M	0.03%	403
2024 Q1	–	Sell	-15,600	Closed	-$1.61M	–	1266
2023 Q4	$1.61M	Sell	15,600 -211,400	-93%	-$20.9M	0.02%	511
2023 Q3	$20.6M	Sell	227,000 -276,600	-55%	-$24.4M	0.23%	107
2023 Q2	$40.7M	Buy	+503,600	New	+$41.1M	0.45%	48

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

LMR Partners's NVO Position: Q2 2026 in Review

LMR Partners sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 63,871 shares — an estimated $2.35M sold.

LMR Partners first reported a position in NVO in Q2 2022 and held it in 12 quarters. The position peaked at $8.3M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

LMR Partners reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 63,871 Novo Nordisk shares in Q2 2026, an estimated $2.35M.
LMR Partners first reported a position in Novo Nordisk in Q2 2022 and held it in 12 quarters.
LMR Partners's Novo Nordisk position peaked at $8.3M in Q2 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.